会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 17. 发明申请
    • WARRANTY AND TIME CRITICAL CONTRACT TRACKING SYSTEM
    • 保证和时间关键合同跟踪系统
    • WO2010141993A1
    • 2010-12-16
    • PCT/AU2010/000719
    • 2010-06-10
    • WILLIAMSON, Christopher
    • WILLIAMSON, Christopher
    • G06Q10/00G06F19/00G06Q30/00
    • G06Q10/06G06Q30/012
    • A system (10) for tracking warranties and other time critical contracts. The system (10) includes a data store (12) for storing at least authentication information for authenticating a user to the system and contract information including start date and end date of the contract being tracked. The system (10) also includes a processor (13) adapted to access the data store and from the information made available in the data store, determining one or dates regarding time critical contracts, and for directing communications with a user via a communications module (14) which is adapted to send and receive information to and from a user's networked device including a mobile telephone (16) or a computer (18) and where the information sent to the device includes at least, an alert reminding the user that the contract is about to expire, in advance of the end date of a contract being tracked.
    • 用于跟踪保修和其他时间关键合同的系统(10)。 系统(10)包括用于至少存储用于向系统认证用户的认证信息的数据存储(12)以及包括正在跟踪的合同的开始日期和结束日期的合同信息。 系统(10)还包括适于访问数据存储器的数据存储器和从数据存储器中可获得的信息中确定一个或关于时间关键合约的日期的处理器(13),以及用于通过通信模块 14),其适于向和从包括移动电话(16)或计算机(18)的用户的联网设备发送和接收信息,并且其中发送到设备的信息至少包括提醒用户合同的警报 即将到期,在合同被追踪的结束日期之前。
    • 20. 发明申请
    • PYRIMIDINONE DERIVATIVES
    • 吡咯烷酮衍生物
    • WO1986001205A1
    • 1986-02-27
    • PCT/GB1985000360
    • 1985-08-13
    • GLAXO GROUP LIMITEDPHILLIPPS, Gordon, HanleyUNDHEIM, KjellWILLIAMSON, ChristopherSTEEPLES, Ian, PhilipBAIN, Brian, MacDonaldBORELLA, Raymond, Andrew
    • GLAXO GROUP LIMITED
    • C07D239/22
    • C07D239/56C07D409/06C07D417/06
    • Bisulphite adducts of compounds of formula (I) wherein R represents a group formula (II), R represents a halogen atom or a trifluoromethyl group; R represents a hydrogen atom or a C1-4 alkyl, C6-10 aryl or benzoyl group; R represents a hydrogen atom or, together with R , represents a -CH2- or -CH2-CH2- chain; and formula (III) represents a C6-10 carbocyclic aromatic group or a carbon-attached heterocyclic group containing a 5- or 6- membered unsaturated heterocyclic ring which ring contains one or more heteroatoms selected from O, N and S and optionally carries a fused carbocyclic ring, which carbocyclic or heterocyclic group may carry one or more substituents selected from halogen atoms, C1-4 alkyl, C1-4 alkanoyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, C1-4 alkylthio, hydroxyl, nitro, cyano and formyl groups, -NR R groups (where R is a hydrogen atom or a C1-4 alkyl group, and R is a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or aroyl group) and C1-4 alkyl groups substituted by one or more hydroxy or -NR R groups and halogen atoms; and salts of such adducts have metaphase arrest abilities and desirably good water solubilities and may be useful in combatting abnormal cell proliferation.
    • 式(I)化合物的亚硫酸氢盐加合物,其中R表示基团式(II),R 1表示卤素原子或三氟甲基; R 2表示氢原子或C 1-4烷基,C 6-10芳基或苯甲酰基; R 3表示氢原子,或与R 2一起代表-CH 2 - 或-CH 2 -CH-链; 并且式(III)表示含有5-或6-元不饱和杂环的C 6-10碳环芳基或含碳连接的杂环基,该环含有一个或多个选自O,N和S的杂原子,并且任选携带稠合 碳环,其中碳环或杂环基可以携带一个或多个选自卤素原子,C 1-4烷基,C 1-4烷酰基,C 1-4烷氧基,C 1-4烷氧基羰基,C 1-4烷硫基,羟基,硝基,氰基和 甲酰基,-NR 4 R 5基团(其中R 4是氢原子或C 1-4烷基,R 5是氢原子或C 1-4烷基,C 1-4 烷酰基或芳酰基)和被一个或多个羟基或-NR 4 R 5基团和卤素原子取代的C 1-4烷基; 并且这种加合物的盐具有中期阻滞能力和期望的良好的水溶性,并且可用于对抗异常细胞增殖。